These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35734391)

  • 1. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
    Thompson KJ; Leon-Ferre RA; Sinnwell JP; Zahrieh DM; Suman VJ; Metzger FO; Asad S; Stover DG; Carey L; Sikov WM; Ingle JN; Liu MC; Carter JM; Klee EW; Weinshilboum RM; Boughey JC; Wang L; Couch FJ; Goetz MP; Kalari KR
    NAR Cancer; 2022 Jun; 4(2):zcac018. PubMed ID: 35734391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
    Vtorushin S; Dulesova A; Krakhmal N
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
    Hartung C; Porsch M; Stückrath K; Kaufhold S; Staege MS; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Pöhler M; Weigert E; Buchmann J; Bürrig KF; Schüler K; Bethmann D; Große I; Kantelhardt EJ; Thomssen C; Vetter M
    Breast Care (Basel); 2021 Dec; 16(6):637-647. PubMed ID: 35082572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting triple-negative breast cancer: A clinical perspective.
    Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
    Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
    Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
    JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
    Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
    Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
    Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
    PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications.
    Syrnioti A; Petousis S; Newman LA; Margioula-Siarkou C; Papamitsou T; Dinas K; Koletsa T
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
    Limsakul P; Choochuen P; Charupanit G; Charupanit K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
    Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
    Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
    Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIbZIP/CREB3L4 Promotes Cell Proliferation via the SKP2-p27 Axis in Luminal Androgen Receptor Subtype Triple-Negative Breast Cancer.
    Ito T; Saito A; Kamikawa Y; Nakazawa N; Imaizumi K
    Mol Cancer Res; 2024 Apr; 22(4):373-385. PubMed ID: 38236913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer.
    Khadela A; Chavda VP; Soni S; Megha K; Pandya AJ; Vora L
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.